Efficacy of 200 IU OnabotulinumtoxinA (Botulinum Toxin Type A) in Patients with Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment: A Retrospective Analysis
The New Journal of Urology · 2025
DOI: 10.33719/nju1550632 ↗Kurz gefasst
Fachartikel in der Zeitschrift The New Journal of Urology, 2025. Verfasst von Ali Egemen Avcı und 3 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.
Abstract (Originalsprache)
Objective
This study aimed to evaluate the efficacy and safety of 200 IU of onabotulinumtoxinA in patients with idiopathic overactive bladder (OAB) and urinary incontinence who had previously shown no response to anticholinergic treatment. This study also sought to examine the impact of a reduction in bladder wall thickness (BWT) on treatment outcomes. Material and Methods: A retrospective analysis was conducted on patients treated between January 2016 and June 2022. Baseline symptoms and quality of life data were compared with those obtained six months post-treatment. Baseline ultrasound (US)-measured post-void residual urine (PVR) and BWT were recorded. Patients with a history of neurological disorders, anticholinergic-naive patients, those diagnosed with bladder cancer, and those with bladder outlet obstruction were excluded.
Results
This study included 60 patients (41 females and 19 males) with a mean age of 36.05 years. At six months, statistically significant improvements were observed in OAB symptoms, including average urination frequency, nocturia, and incontinence episodes (p
Förderung
- None
Zitieren
APA
Avcı, A. E., Çakıroğlu, B., Arıkan, M. G., & Çulpan, M. (2025). Efficacy of 200 IU OnabotulinumtoxinA (Botulinum Toxin Type A) in Patients with Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment: A Retrospective Analysis. The New Journal of Urology. https://doi.org/10.33719/nju1550632
Vancouver
Avcı AE, Çakıroğlu B, Arıkan MG, Çulpan M. Efficacy of 200 IU OnabotulinumtoxinA (Botulinum Toxin Type A) in Patients with Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment: A Retrospective Analysis. The New Journal of Urology. 2025. doi:10.33719/nju1550632
BibTeX
@article{Avc2025,
author = {Avcı, Ali Egemen and Çakıroğlu, Basri and Arıkan, Mehmet Gürkan and Çulpan, Meftun},
title = {Efficacy of 200 IU OnabotulinumtoxinA (Botulinum Toxin Type A) in Patients with Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment: A Retrospective Analysis},
journal = {The New Journal of Urology},
year = {2025},
doi = {10.33719/nju1550632}
}
EUVIMED